Kyntra Bio Q2 FY26 returns to profit at $12 million; revenue turns to $(1.5) million

Reuters2026/08/13 20:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kyntra Bio posted Q2 revenue of $(1.47) million, swinging from $1.35 million a year earlier.
Net income from continuing operations turned to $12 million, or $2.96 per share, from a $13.7 million loss.
Operating loss widened to $17.57 million from $12.05 million, while interest and other income rose to $29.55 million on a $30.94 million gain.
Cash, cash equivalents, investments, and accounts receivable totaled $95.7 million at June 30; funding runway projected into 2028.
FG-3246 Phase 2 enrollment continued with interim analysis slated for 4Q 2026; roxadustat Phase 3 in LR-MDS targeted to start 4Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131602PRIMZONEFULLFEED9809824) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kyntra Bio Q2 FY26 returns to profit at $12 million; revenue turns to $(1.5) million

You may also like

Crypto prices